Human Tumor Assay Journal is resource for physicians, cancer researchers, patients, and others interested in the field of Individualized Tumor Response Testing (ITRT), which, broadly defined, means testing “living” cancer cells and tissues in cell culture or organ culture to determine the “response” of the cells (or tissues) to putative anticancer drugs. This information is most typically used to make treatment decisions involving drug selection for use in cancer chemotherapy.
ITRT is also known as “personalized chemotherapy selection,” “cytometric cancer profiling,” “chemosensitivity testing,” “chemoresistance testing,” “chemoresponse testing,” “drug resistance testing,” “cell culture drug resistance testing” (CCDRT), “cell culture drug response testing,” “functional profiling,” and by a variety of proprietary names used by commercial laboratories.
Larry Weisenthal, MD,PhD
Huntington Beach, CA, USA